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Abstract
The microenvironment of a tumor can influence both the morphology and the behavior of cancer cells which, in turn, can
rapidly adapt to environmental changes. Increasing evidence points to the involvement of amoeboid cell migration and
thus of cell blebbing in the metastatic process; however, the cues that promote amoeboid cell behavior in physiological and
pathological conditions have not yet been clearly identified. Plasminogen Activator Inhibitor type-1 (PAI-1) is found in high
amount in the microenvironment of aggressive tumors and is considered as an independent marker of bad prognosis. Here
we show by immunoblotting, activity assay and immunofluorescence that, in SW620 human colorectal cancer cells, matrix-
associated PAI-1 plays a role in the cell behavior needed for amoeboid migration by maintaining cell blebbing, localizing
PDK1 and ROCK1 at the cell membrane and maintaining the RhoA/ROCK1/MLC-P pathway activation. The results obtained
by modeling PAI-1 deposition around tumors indicate that matrix-bound PAI-1 is heterogeneously distributed at the tumor
periphery and that, at certain spots, the elevated concentrations of matrix-bound PAI-1 needed for cancer cells to undergo
the mesenchymal-amoeboid transition can be observed. Matrix-bound PAI-1, as a matricellular protein, could thus represent
one of the physiopathological requirements to support metastatic formation.
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Introduction
The amoeboid and mesenchymal modes of migration are both
used by cancer cells for moving in their environment and invading
the surrounding tissues. Inhibition or up-regulation of specific
molecular pathways can determine the choice of migration mode
and can also lead to switch to the other type of cell movement, a
phenomenon known as mesenchymal-amoeboid transition (MAT)
or amoeboid-mesenchymal transition (AMT) [1,2,3,4]. Amoeboid
migration is characterized by the presence of round cells and
membrane blebbing [5] and requires RhoA and its main effector
Rho-associated Coil-containing Protein Kinase 1 (ROCK1),
which regulates the phosphorylation of Myosin Light Chain
(MLC) and Acto-Myosin contractility during the bleb life cycle
[5,6,7]. Moreover, 3-Phosphoinositide-Dependent-Protein-Kinase
1 (PDK1), an important regulator of cortical MLC phosphoryla-
tion, indirectly activates ROCK1 at the plasma membrane and
thereby promotes amoeboid cell motility [8]. On the other hand
and differently from the mesenchymal mode, amoeboid migration
does not require pericellular proteolysis [3]. However, the cues
that promote the amoeboid behavior in physiological and
pathological conditions have not been clearly identified yet [9].
The cell microenvironment can influence both the morphology
and behavior of cancer cells (reviewed recently by Mantovani
[10]). Plasminogen Activator Inhibitor type-1 (PAI-1) is found in
high amount in the microenvironment of aggressive tumors and is
considered as a marker of bad prognosis [11,12]. PAI-1 is part of
the Plasminogen Activator (PA) system that includes also urokinase
Plasminogen Activator (uPA) and its receptor (uPAR). In addition
to catalyzing the degradation of the extracellular matrix and
modulating cell adhesion [13,14], various components of the PA
system also influence cell migration [15,16,17]. Binding of PAI-1
to Vitronectin (VN) stabilizes PAI-1 in its active conformation.
Upon binding to uPAR, PAI-1 decreases its affinity for VN in the
matrix and simultaneously increases the affinity for endocytic
receptors, such as the low-density Lipoprotein Receptor-related
Protein (LRP) [18,19,20]. It has been suggested that the urokinase-
dependent PA system modulates cell migration through the Ras/
ERK pathway and the Rho/ROCK signaling cascade [21,22].
Numerous studies have shown that uPAR signals through various
pathways (Ras-Mitogen-Activated Protein Kinase (MAPK) path-
way, Tyrosine kinases, Focal Adhesion Kinase (FAK), Src and Rac
GTPase) [23,24,25,26] and a recent review has stressed the role of
uPAR, in association with Integrins or Vitronectin, in regulating
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a molecule participating in the regulation of the rapid attachment/
detachment of cells required for migration [14,15,16,17,18,19], no
specific signaling linked to this PAI-1 conformation has yet, to our
knowledge, been described.
In this study, we focused on the role of immobilized, active PAI-
1 in supporting blebbing of SW620 colorectal cancer cells and
investigated the signaling cascades involved in PAI-1 promotion of
cell blebbing, a typical feature of amoeboid movement. We show
that SW620 cells seeded on plates coated with immobilized, active
PAI-1 are characterized by more frequent blebbing, colocalization
of PDK1 and ROCK1 at the cell membrane and long lasting
activation of the RhoA/ROCK1 pathway in comparison to cells
seeded on collagen. Moreover, in SW620 cells seeded on
immobilized, active PAI-1 we observed membrane depositions.
Finally, modeling of the PAI-1 ‘‘cycle’’ (its expression/secretion as
a soluble protein, deposition in the matrix, activity or latency,
interactions with VN, ‘‘consumption’’ as part of a complex with
uPAR and uPA and subsequent internalization) indicates that
secreted PAI-1 by tumor cells is not homogeneously distributed at
the tumor periphery, but rather localized in high-concentration
deposits particularly in tumors characterized by the presence of
invaginations [28]. In this study we suggest that the most
aggressive cancer cells could ‘‘use’’ these high-concentration spots
of matrix-bound PAI-1 to undergo mesenchymal-amoeboid
transition and escape using the amoeboid mode of migration;
therefore PAI-1 could be part of a new physio-pathological
mechanism supporting metastatic escape.
Results and Discussion
Immobilized, active PAI-1 supports cell blebbing
To specifically assess the role of matrix-bound PAI-1 in
supporting membrane blebbing of cancer cells, we cultured
SW620 human colorectal cancer cells in plates coated with PAI-
1 14-1b, a mutant PAI-1 which is active for 500 hours. When
cultured on non-coated plates and medium supplemented with
serum (multi-molecular environment), SW620 cells could be
classified in three main morphological categories: spindle-shaped,
blebbing and round cells (Fig. 1A). The proportion of spindle-
shaped and blebbing cells was roughly the same (40%).
Conversely, when SW620 cells were seeded in plates coated with
PAI-1 14-1b or collagen in the absence of serum (mono-molecular
environment), their distribution in the three morphological
categories differed according to the type of environment.
Specifically, the proportion of blebbing cells was always higher
in cultures seeded on PAI-1 14-1b than on collagen (Fig. 1B and
C, Fig. S1), particularly at the 19 h time-point. This was not due to
differences in cell adhesion because the same number of adherent
cells was found in both conditions (Fig. S2A). In addition, the
number of blebbing cells was proportional to the concentration of
PAI-1 14-1b used to coat the plates (from 2 to 40 mg/cm
2) with
saturation of the effect at 20 mg/cm
2 (Fig. 1D). This concentration
was thus used for all the subsequent experiments. Bleb formation/
retraction appeared to be a quick process (Video S1), similarly to
what has been previously described by others [29,30]. Experi-
mentally, whatever the microenvironment, blebbing cells showed
no b-Tubulin re-organization, but characteristic F-Actin rings in
blebs (Fig. 1E). Moreover, clusters of b1 Integrin associated with
the F-Actin cytoskeleton were observed at the membrane of
spindle-shaped cells, whereas they were absent in blebbing cells
(Fig. 1F). Finally, in some blebbing cells, Ezrin expression was
restricted to blebs and colocalized with F-Actin [5,30] (Fig. 1G).
This is in coherence with Ezrin role in bleb dynamics [30], i.e.
stabilizing newly formed F-Actin-transmembrane protein interac-
tions. In conclusion, the blebbing cells experimentally observed in
2D cultures in the presence of immobilized, active PAI-1 have the
main characteristics described by others before [3].
These results indicate that PAI-1 is the first matrix protein
supporting cell blebbing in 2D cultures and show that when
studying the behavior of cancer cells it is crucial to take into
consideration not only the choice of 2D or 3D culture systems [9],
but also the nature, conformation and concentration of the
molecules present in the environment.
Immobilized, active PAI-1 maintains the RhoA/ROCK
pathway activation
As blebbing can occur in a ROCK1-dependent manner [31],
we then assessed the effects of Y27632, a ROCK inhibitor, on the
morphology of SW620 cells seeded either on PAI-1 14-1b- or on
collagen-coated plates. As expected, addition of Y27632 caused a
dramatic decrease in the number of blebbing cells (Fig. 2A) and an
increase of spindle-shaped cells (data not shown), indicating that
the observed blebbing process is ROCK-dependent. Then we
examined the two main pathways leading to ROCK activation:
Caspase 3 and RhoA [31]. In our experimental conditions,
ROCK activation was Caspase 3-independent, with no apoptosis
as attested by the absence of cleaved Caspase 3 (Fig. 2B), of DNA
cleavage and by the normal growth curves of cells seeded on PAI-1
14-1b or collagen (Fig. S2B). Conversely, RhoA was induced in
blebbing cells 10 min after seeding in both experimental
conditions (data not shown). However, while in blebbing cells
seeded on PAI-1 14-1b, RhoA activation increased with time till
the 19 h time-point (Fig. 2C), in blebbing cells seeded on collagen,
RhoA activation decreased rapidly after the 3 h time-point
concomitantly with the number of blebbing cells (Fig. 2C).
Accordingly, at the 19 h time-point, RhoA activity was higher in
SW620 cells seeded on PAI-1 14-1b than in those seeded on
collagen (Fig. 2D). Similarly, the amount of phosphorylated MLC
(MLC-P) at the 19 h time-point was also higher in cells seeded on
PAI-1 14-1b than in cells seeded on collagen (Fig. 2E). Finally,
quantification by using the Axiovision 4.5 ‘‘Colocalization’’
module (Zeiss) indicated that ROCK1 and PDK1 were more
frequently colocalized at the membrane in SW620 cells seeded on
PAI-1 14-1b than in cells seeded on collagen. This phenomenon
was more evident at the 30 min (Fig. 2F) than at the 19 h time-
point (Fig. S3A). Specifically, as shown by the illustrative example
in Figures 2G and S3A, at any time-point, ROCK1 was
preferentially localized near the cell membrane in SW620 cells
seeded on PAI-1 14-1b, while it was homogeneously distributed in
the whole cell in cells seeded on collagen. Conversely, PDK1 was
always localized at the cell membrane whatever the environment
and the time-point (Fig. 2G, Fig. S3A). These observations are in
agreement with the need to recruit PDK1 and ROCK1 to the cell
membrane to allow cell blebbing, as suggested by Pinner and
Sahai [8]. These results indicate that immobilized, active PAI-1
supports cell blebbing through activation of the RhoA/ROCK1/
MLC-P pathway and colocalization of PDK1 and ROCK1 at the
cell membrane. This finding could help understanding how PAI-1
contributes to cancer development and progression.
The Plasminogen Activator system influences cell
blebbing
The PA system has been involved in cancer progression through
its proteolytic activity via uPA, by regulating cell adhesion via PAI-
1 [13], through its involvement in mechanical transmission [14,32]
and finally through its role in cell migration [15,17,33] (Fig. S4).
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PLoS ONE | www.plosone.org 2 February 2012 | Volume 7 | Issue 2 | e32204Figure 1. Immobilized, active PAI-1 supports cell blebbing. (A) When SW620 human colon cancer cells are cultured in the presence of serum
they can be classified in three main morphological types: spindle-shaped, blebbing and round. Bar, 10 mm. The percentage of spindle-shaped (B) and
blebbing cells (C) is influenced by the length of time SW620 cells have been in contact with immobilized, active PAI-1 14-1b, collagen or the matrix
secreted by control cells (seeded on non-coated plates). Data are the mean 6 s.e.m. of eight independent experiments; *: P,0.05, ** P,0.01. (D)
Percentage of spindle-shaped, blebbing and round SW620 cells in plates coated with increasing concentrations of PAI-1 14-1b. Data are the mean 6
s.e.m. of four independent experiments; *: P,0.05, **: P,0.01, ***: P,0.001. Analysis by immunostaining and 3D reconstruction of the expression of
(E) F-Actin and b-Tubulin, (F) F-Actin and b1 Integrin (arrowheads point to b1 Integrin clusters), and (G) F-Actin and Ezrin (arrowheads point to
colocalization in blebs) in blebbing SW620 cell seeded on PAI-1 14-1b and spindle-shaped SW620 cell seeded on collagen at the 19 h time-point after
seeding. Bar, 5 mm.
doi:10.1371/journal.pone.0032204.g001
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PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e32204SW620 cells seeded on PAI-1 14-1b or collagen expressed uPA
and uPAR, but the distribution of uPAR in blebbing cells was not
homogenous. Indeed, uPAR expression was higher in the basal
part of the cells and this could be of importance for cells on matrix-
bound PAI-1 (Fig. 3A). Moreover, in blebbing cells, uPAR
colocalized at the cell membrane with uPA (Fig. S3B) and PAI-1
Figure 2. Immobilized, active PAI-1 maintains the RhoA/ROCK pathway activation. (A) Percentage of blebbing SW620 cells seeded on PAI-
1 14-1b or collagen in the presence of the ROCK inhibitor Y27632 (Y27) (10 mM) at 19 h time-point after seeding. Data are the mean 6 s.e.m. of three
independent experiments; **: P,0.01. (B) Detection of cleaved Caspase 3 by immunoblotting in SW620 cells seeded on non-coated plates (control),
PAI-1 14-1b or collagen 19 h and 24 h after seeding. SW620 cells treated with 1 mM staurosporin (St.) for 24 h were used as positive control. b-Tubulin
served as loading control. (C) RhoA activity and proportion of blebbing cells in SW620 cells seeded on PAI-1 14-1b or collagen at different time-points
after seeding. Values were normalized to the effects at 3 h for each condition. Data are the mean 6 s.e.m. of four independent experiments. (D)
Quantification following immunoblotting of active RhoA relative to total RhoA in SW620 cells seeded on PAI-1 14-1b or collagen for 19 h. Data are
the mean 6 s.e.m. of three independent experiments; ***: P,0.001. (E) Quantification following immunoblotting of phosphorylated MLC (MLC-P)
relative to b-Tubulin (loading control) expression in SW620 cells seeded on PAI-1 14-1b or collagen for 19 h. Data are the mean 6 s.e.m. of three
independent experiments; *: P,0.05. (F) Percentage of ROCK1 colocalization with PDK1 relative to total ROCK1 expression in blebbing SW620 cells
seeded on PAI-1 14-1b or collagen for 30 min. Data are the mean 6 s.e.m. of the analysis of ten blebbing cells in each microenvironment; **: P,0.01.
(G) Expression of PDK1 and ROCK1 in blebbing SW620 cells seeded on PAI-1 14-1b or collagen for 30 min. The colocalization of PDK1 and ROCK1 is
shown and their signal distributions are compared. Bar, 5 mm.
doi:10.1371/journal.pone.0032204.g002
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PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e32204(Fig. S3C), which was strongly expressed in blebs (Fig. 3B),
suggesting that [uPAR:uPA:PAI-1] complexes might be more
easily formed at the membrane of cells in such conditions.
We then tried to understand to which extent the formation of
[uPAR:uPA:PAI-1] complexes is needed for maintaining cell
blebbing. To this aim, we first tried to impair the formation or
internalization of the [uPAR:uPA:PAI-1] complex by using
antibodies against uPA and uPAR. Addition of anti-uPA or anti-
uPAR antibodies to the culture medium led to a significant
decrease in the number of blebbing cells in cultures seeded on
PAI-1 14-1b (Fig. 3C). We then grew SW620 cells in plates coated
with PAI-1 R, a dominant negative PAI-1 mutant that binds
transiently and weakly to uPA [34]. Also in this case the number of
blebbing cells decreased (Fig. 3D). However, addition of soluble
PAI-1 14-1b had no effect on the blebbing of cells seeded on non-
coated plates (Fig. 3E), thus ruling out a positive influence of
soluble PAI-1 on the blebbing process and stressing the specific
role of matrix-bound PAI-1 in the same process. Taken together,
these data suggest that the optimal situation for cancer cell
blebbing is the presence of uPAR together with active uPA and
immobilized, active PAI-1. LRP does not seem to be directly
required for cell blebbing because seeding cells on plates coated
with PAI-1 R76E, a PAI-1 mutant that cannot bind to LRP, only
slightly modified the number of blebbing cells (Fig. 3D). However,
we cannot exclude the participation of other internalization
receptors, such as Endo 180 or GP 330, in uPAR recycling
[35,36,37]. Moreover, the localization of uPAR at the cell
membrane of blebbing cells suggests that uPAR could participate
in the process of polarization involved in cell amoeboid migration.
Indeed, it has been stressed [27] that the multiple functions and
interactions of uPAR and uPA must be taken into account when
trying to understand the process of cancer cell migration,
especially the finely tuned crosstalk between cancer and stromal
cells (in terms of changes in the microenvironment).
Finally, at early time-points after seeding on non-coated plates,
little spots that were strongly positive for PAI-1 expression were
observed around the membrane of blebbing cells on immobilized,
active PAI-1 and non-coated plates in about 30% of the entire cell
population, but not on collagen coated plates (Fig. 3F, Video S2).
This suggests that membrane depositions are formed at the
membrane of blebbing cells, as previously described in conven-
tionally migrating cells [38,39,40] and in blebbing cells [41].
Membrane depositions can influence processes as diverse as cell
polarity, differentiation, migration, chemotherapy resistance,
immuno-regulation, inflammation, coagulation, angiogenesis and
cancer metastasis [42] and to act as mediators of intercellular
communication in cancer [42]. Colorectal cancer cells, among
which also SW620 cells, can release exosome-like membrane
depositions [43,44]. Proteomic analysis of these structures in
SW620 cells showed the presence of PAI-1 and uPA, but no
uPAR, PDK1 or ROCK1 (Lim JWE et al., 2010, http://www.
ludwig.edu.au/archive/JustinLimSupplemental/index.htm). Simi-
larly, in our experimental conditions, membrane depositions
contained PAI-1 (Fig. 3F and G, Fig. S3D, Video S2 and Video
S3) and uPA (Fig. S3F), but not uPAR. However, both PDK1 and
ROCK1 were found in these structures (Fig. 3H, Video S4), as
well as Flotillin1 (Fig. 3G, Fig. S3E) and b1 Integrin (Fig. S3D and
E) that have been previously detected in exosomes and ectosomes.
Moreover, PAI-1 strongly colocalized with the cell membrane
(labeled with fluorescent wheat germ agglutinin), decorated
membrane deposits, and partially colocalized with Flotillin1 and
b1 Integrin (Fig. 3F and G, Fig. S3D).
Such membrane depositions were never observed in cells seeded
on collagen (data not shown), suggesting that immobilized, active
PAI-1 could act as an indirect promoter of accumulation at the cell
membrane of various molecules and vesicle/membrane deposition
by supporting blebbing, which in turn also favors accumulation at
the cell membrane and vesicle/membrane deposition. Matrix-
bound PAI-1 thus is, to our knowledge, the first matricellular
protein [45] to influence the formation of such membrane
depositions. Moreover, PAI-1 in membrane deposits was also
detected with an antibody directed against active PAI-1 (data not
shown), thus suggesting a unique role for blebbing in the
microenvironmental modification process. Furthermore, mem-
brane deposits formation and accumulation appeared to be
polarized (Fig. 3F, G and H), as schematically summarized in
Figure 3I. Each cell might thus participate in the modification of
its immediate environment, including the presence of spots of
active PAI-1 in the matrix, defining qualitatively and topologically
a new microenvironment for itself but also for other cells, as
stressed in previous studies [46].
Altogether our work suggests that, in SW620 cells, formation of
[uPAR:uPA:PAI-1] complexes, particularly with matrix-bound
PAI-1, is pivotal in supporting cell blebbing. The higher uPAR
expression in the basal part of cells seeded on PAI-1 14-1b (Fig. 3A)
suggests that such complexes are more likely to be formed in the
adherent part of the cell. This is well in line with previous studies
showing that VN expression is localized between the cell
membrane and the extracellular matrix [47]. As [uPAR:uPA:
PAI-1] complex formation is needed to activate the Rho pathway
and to support cell blebbing and since uPAR is not a
transmembrane receptor, we think that this effect might not occur
through direct signal transduction (which requires a transmem-
brane receptor), but rather through biomechanical signal trans-
mission (thus implicating an unknown co-actor), as previously
mentioned [32] (Fig. 4). The role of matrix-bound PAI-1 in
blebbing could therefore be to promote many new and weak
interactions between matrix-bound [uPAR:uPA:PAI-1] complexes
and cofactors at the cell membrane, that might lead to amoeboid
cell behavior.
Figure 3. The Plasminogen Activator system influences cell blebbing. (A) Number of stained pixels of the uPAR immunostaining z-profile in
SW620 cells seeded on PAI-1 14-1b or collagen for 19 h. Data are the mean 6 s.e.m. of the analysis of thirty blebbing cells; *: P,0.05, **: P,0.01. (B)
Expression of F-Actin and PAI-1 in blebbing SW620 cells seeded on PAI-1 14-1b for 19 h. (C) Percentage of blebbing SW620 cells (3 h after seeding)
seeded on plates coated with PAI-1 14-1b or non-coated plates (Control) and in which the medium was supplemented with IgG, anti-uPA or anti-
uPAR antibodies. Data are the mean 6 s.e.m. of three independent experiments; ***: P,0.001. (D) Percentage of blebbing SW620 cells seeded on
PAI-1 14-1b, PAI-1 R76E or PAI-1 R at the 3 h and 19 h time-points. Data are the mean 6 s.e.m. of three independent experiments; *: P,0.05, **:
P,0.01. (E) Percentage of blebbing SW620 cells (3 h after seeding) seeded on plates coated with PAI-1 14-1b or non-coated plates (Control) and in
which the medium was supplemented with soluble PAI-1. Data are the mean 6 s.e.m. of three independent experiments; **: P,0.01, ***: P,0.001. (F)
Localization of PAI-1 at the membrane (stained with wheat germ agglutinin) in SW620 cells seeded on non-coated plates for 30 min. (G) Flotillin1 and
PAI-1 expression in SW620 cells seeded on non-coated plates for 30 min. (H) PDK1 and ROCK1 expression in SW620 cells seeded on PAI-1 14-1b for
30 min. (I) Schematic representation of deposits, which include PAI-1, uPA, PDK1, ROCK1, Flotillin1 and b1 Integrin, of blebbing cells in a 2D
microenvironment. Bar, 5 mm.
doi:10.1371/journal.pone.0032204.g003
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effects on amoeboid cell behavior
In order to durably maintain membrane blebbing, PAI-1 has to
be present in the matrix at very high concentrations. To further
investigate the scenario suggested by our experimental observa-
tions, we first carried out an in silico simulation aiming at modeling
PAI-1 deposition around a growing tumor (Fig. 5A) by
implementing a cellular automata simulation of PAI-1 secretion
by growing tumor cells. This model showed that a minimal
mechanism, i.e. the random growth of tumor cells together with
the diffusion/deposition of secreted PAI-1 (or of any secreted
protein) on the available matrix, is enough to account for the
highly heterogeneous distribution (spots) of matrix-bound PAI-1 at
the tumor periphery. Then we used a more refined simulation to
describe how the behavior of cancer cells is modified by the
presence of increasing/decreasing concentration of immobilized,
active PAI-1. This is a more ‘‘realistic’’ agent-based simulation of
tumor growth, involving more cell states and different molecular
species, although still simpler than the biological reality and
restricted to what we think to be the main actors (Fig. S5, Video
S5). It reproduces both the observed structure of a tumor and its
surroundings as well as the heterogeneous distribution of matrix-
bound PAI-1 around the tumor [12]. A given cell at the periphery
of the tumor can ‘‘meet’’ a spot of high concentration of matrix-
bound PAI-1 and ‘‘use’’ it for maintaining blebbing. Overall, both
simulation studies support a mechanism whereby all tumor cells
produce and deposit enough PAI-1 to maintain the blebbing of a
very small fraction of them. This behavior is favored by the local
morphology and tumor growth history, thus explaining the
persistence of a microenvironment locally favorable to blebbing.
This feature of the tumor microenvironment can be pivotal in
modulating (or influencing) the behavior of a single cell following
variation of the concentration of available matrix-bound PAI-1. In
Figure 5C, we describe the dynamical transitions between the
mesenchymal and amoeboid state of a single cell depending on the
microenvironment. This two-state diagram is supported by our
experimental data, showing that, in the presence of high
concentrations of matrix-bound PAI-1, more cells are in the
amoeboid state (Fig. 1D and Fig. S1), a situation associated with
the activation of the RhoA/ROCK1/MLC-P signaling pathway.
We thus hypothesized that, when the extracellular matrix of a
tumor cell is progressively enriched in PAI-1 (x-axis), the cell
mesenchymal state maintained by adhesion via Integrins (y-axis) is
perturbed. Indeed, as observed by others, PAI-1 is an efficient
perturbator of Integrin-dependent adhesion [19,48]. Specifically,
high concentrations of PAI-1 disrupt the first equilibrium state and
Figure 4. Involvement of the Plasminogen Activator system in the signaling to regulate the transition between mesenchymal and
amoeboid migration. uPAR can interact with different types of Integrins and participates in the activation of the MEK/ERK and Rac pathways, both
leading to mesenchymal migration. Active, matrix-bound PAI-1 blocks the association of Integrin and uPAR with the extracellular matrix and
subsequently supports cell blebbing by activating the RhoA pathway. If only matrix-bound PAI-1 is available, as in our experimental model, the RhoA
pathway is activated either through biomechanical transmission (implicating an unknown co-actor) or transduction (implicating a transmembrane
receptor; altogether these events might lead to amoeboid migration.
doi:10.1371/journal.pone.0032204.g004
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where adhesion becomes PAI-1-dependent. If all the required
conditions are met, the cell starts to move on matrix-bound PAI-1,
‘‘consumes’’ it by internalizing it together with [uPA:uPAR]
complexes and leaves the high-concentration PAI-1 spot [28].
Experimentally, cells seeded on immobilized, active PAI-1
progressively consume it as indicated by the time-dependent
decrease of PAI-1 14-1b concentration (and effect), while their
production of endogenous PAI-1 is not modified (Fig. 5B). As a
consequence, cell spreading is again favored by reengagement of
Integrin-dependent adhesion (in our conditions, after the 19 h
time-point, Fig. 1B), until the cell reaches a new equilibrium, i.e.
the mesenchymal state. These MAT and AMT transitions are
mathematically modeled as a switch between two dynamically
stable states associated with amoeboid and mesenchymal behavior
(Fig. 5C). The changes at different matrix-bound PAI-1 concen-
trations correspond to the hysteretic cycle predicted by our model.
Our integrated scenario for metastatic escape is based on a
succession of ‘‘hiving cycles’’ in which the microenvironment is
controlled internally by the tumor growth and secretions,
switching cells (when the matrix-bound PAI-1 concentration is
high enough) from the mesenchymal state to the amoeboid state.
This allows the cell to escape from the primary tumor and,
possibly, to generate a secondary tumor, when switching back to
the mesenchymal state (at low concentrations of matrix-bound
PAI-1). Although migration of blebbing cells is an individual and
rare phenomenon, as illustrated by the presence of a single cell
migrating towards other cells in a PAI-1-coated well seeded with
SW620 cancer cells (Fig. 5D, Video S6), cycling between
amoeboid and mesenchymal behavior could explain early cancer
cell escape, in which phases of proliferation and migration (leading
to metastasis) can take place [28].
Based on this model we might also hypothesize that the most
aggressive cancer cells could ‘‘use’’ the spots of high concentration
of matrix-bound PAI-1 to undergo mesenchymal-amoeboid
transition, following a physiological hysteresis [28], to deposit
membrane depositions and to escape using the amoeboid mode of
migration. VN is probably deposited in a similar fashion (i.e., in
the extracellular matrix around some cell clusters) [49], thus
offering multiple binding sites to PAI-1, which can be stabilized in
its active conformation.
It is now recognized that the blebbing and mesenchymal states
both involve rapid changes that are viewed as a response to
specific cues from the microenvironment [1]. Experimentally, a
Figure 5. Modeling PAI-1 deposition and simulation of its possible effects on amoeboid cell behavior. (A) Cellular-automata simulation
of PAI-1 secretion, diffusion and deposition (vertical axis) in tumors of different cell size (10, 100 and 500 cells). (B) Detection of endogenous PAI-1 and
recombinant PAI-1 14-1b by immunoblotting in SW620 cells seeded on PAI-1 14-1b at different time-points. Signal intensities were normalized to the
expression of b-Tubulin. (C) Mathematical modeling of the possible effects of changes in the concentration of matrix-bound PAI-1 in the hysteretic
cycle between amoeboid and mesenchymal behavior. (D) Amoeboid pseudopodal migration of a blebbing SW620 cell seeded on PAI-1 14-1b (17 h
after seeding). Arrowhead indicates a pseudopod. Speed was evaluated at 0.4 mm/min (see also Video S6). (E) Transition between blebbing and
spindle-shaped morphology, and back, in blebbing morphology in a SW620 cell (w) seeded on PAI-1 14-1b (7 h after seeding) (see also Video S7). Bar,
10 mm.
doi:10.1371/journal.pone.0032204.g005
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(Fig. 5E, Video S7), or stay spread (Video S8).
Our results highlight that amoeboid cell migration is supported
by matrix-bound PAI-1 in a 2D environment. It is predominantly
‘‘single cell, blebby, covering local short distances’’, and, as such,
consistent with the way cancer metastases reach distant sites
[9,50]. However, the PAI-1 effect on cell blebbing is observed only
when PAI-1 is present at high concentration, in the active
conformation and immobilized; moreover, PAI-1 binding to LRP
or its internalization does not seems to be indispensable based on
our observations. The availability of uPA is required for binding to
matrix-bound PAI-1, which is its immediate, localized and
preferred inhibitor, rather than for its proteolytic activity [51].
The formation of [uPAR:uPA:PAI-1] complexes leads to weak
adhesion [32], but rapid turnover [28], especially of uPAR which
seems to be localized in blebs, like ROCK1 and PDK1, leading to
the local persistence of blebbing [8].
All together our results show that blebbing cells in contact with
high concentrations of matrix-bound PAI-1 extend the duration of
blebbing and display the main requirements for amoeboid
behavior. A tumor environment rich in matrix-bound PAI-1
might thus provide interconnected inputs that modulate cell
adhesion and cytoskeletal organization, impacting on tumor cell
shape, cell polarization and finally, mode of migration. PAI-1 is
the first matrix-bound protein described as maintaining mem-
brane blebbing of cancer cells supporting amoeboid behavior, and
thereby most possibly favoring metastatic escape.
Materials and Methods
Cell line and microenvironments
The SW620 human colorectal cancer cell line (from ATCC)
was maintained in Leibovitz L-15 medium (Invitrogen) supple-
mented with 10% fetal calf serum (FCS) (Sigma-Aldrich), 100 U/
ml penicillin and 100 mg/mL streptomycin (Invitrogen) at 37uCi n
a0 %C O 2 humidified atmosphere. Cells in the exponential phase
of growth were trypsinized with Trypsin-EDTA (Invitrogen),
suspended in serum-free medium containing 1% BSA (Sigma-
Aldrich) and 200,000 cells per cm
2 were seeded in 1.9 cm
2 wells
on acidified glass cover-slips coated with PAI-1 14-1b (the stable
active form of PAI-1 that shows full inhibitory activity and binds to
VN and LRP), PAI-1 R (stable active form with transient
inhibitory activity; binds to VN), PAI-1 R76E (stable active form
with full inhibitory activity; binds to VN but not to LRP) (kindly
provided by Dr. Daniel A Lawrence), or collagen ([Ref. 354236]
BD Biosciences) as indicated. In all experiments, unless otherwise
stated, PAI-1 was used at the concentration of 20 mg/cm
2 and
collagen at 10 mg/cm
2. Non-coated acidified glass cover-slips were
used for controls. The ROCK inhibitor Y27632 (10 mM; [Ref.
Y0503] Sigma-Aldrich), staurosporin (1 mM; [Ref. 9953] Cell
Signaling), rabbit anti-uPA (H-140) antibody (15 mg/mL; [Ref. sc-
14019] Santa Cruz Biotechnology, Inc.), rabbit anti-uPAR (FL-
290) antibody (15 mg/mL; [Ref. sc-10815] Santa Cruz Biotech-
nology, Inc.), rabbit IgG (15 mg/mL; [Ref. sc-2027] Santa Cruz
Biotechnology, Inc.) and soluble PAI-1 14-1b (76 mg/mL,
corresponding to 20 mg/cm
2) were also added to the medium
when required.
Adherence assay
200,000 cells per cm
2 were seeded in 1.9 cm
2 wells on acidified
glass coverslips coated with PAI-1 14-1b or collagen in Leibovitz
L-15 medium supplemented with 1% BSA, 100 U/ml penicillin,
100 mg/mL streptomycin and incubated at 37uC in a 0% CO2
humidified atmosphere for 3, 6, 19 and 24 hours. Adherent cells
were fixed in 3.65% formaldehyde for 10 min and stained with
0.2% crystal violet at room temperature for 15 min. After
solubilization of the crystal violet dye with 1% SDS, the number
of adherent cells was calculated by measuring the absorbance at
570 nm with a Sunrise plate reader (Tecan).
Cell growth assay
200,000 cells per cm
2 were seeded in 1.9 cm
2 wells on acidified
glass cover-slips coated with PAI-1 14-1b or collagen in Leibovitz
L-15 medium supplemented with 1% BSA, 100 U/ml penicillin,
100 mg/mL streptomycin and incubated at 37uC in a 0% CO2
humidified atmosphere for 6 hours. Then the medium was
replaced by Leibovitz L-15 medium supplemented with 10%
FCS, 100 U/ml penicillin and 100 mg/mL streptomycin. After 24,
48 and 72 hours, cells were trypsinized with Trypsin-EDTA
(Invitrogen) and counted with a Malassez counting chamber.
Immunoblotting
Cells were washed in phosphate-buffered saline (PBS) and lysed
directly in 50 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA,
10% glycerol, 0.5% NP40 supplemented with protease inhibitor
cocktail ([Ref. 11836170001] Roche). Denatured proteins were
separated by electrophoresis on 12% SDS-polyacrylamide or 4–
12% Bis-Tris gels and transferred either to polyvinylidene fluoride
or nitrocellulose membranes, then blocked with 5% non-fat dry
milk-PBS at room temperature for 1 hour. Membranes were
incubated with rabbit anti-MLC-P (Thr 18)-R (dilution 1:500;
[Ref. sc-19848-R] Santa Cruz Biotechnology, Inc.), rabbit anti-
PAI-1 (H-135) (dilution 1:2000; [Ref. sc-8979] Santa Cruz
Biotechnology, Inc.) or rabbit anti-cleaved Caspase 3 (dilution
1:500; [Ref. 9661] Cell Signaling) primary antibodies at 4uC
overnight and then with HRP-conjugated goat anti-rabbit
secondary antibodies (dilution 1:2,000; [Ref. sc-2004] Santa Cruz
Biotechnology, Inc.) at room temperature for 1 hour. The signal
was detected with ECL or ECL
+ reagents (Amersham Biosciences).
Mouse anti-a-Tubulin (dilution 1:10,000; [Ref. T6199] Sigma-
Aldrich) or mouse anti-b-Tubulin (TUB 2.1) antibodies (dilution
1:2,000; [Ref. sc-58886] Santa Cruz Biotechnology, Inc.) were
used to control equal loading and binding was detected with a
HRP-conjugated goat anti-mouse secondary antibody (dilution
1:2,000; [Ref. sc-2005] Santa Cruz Biotechnology, Inc.).
RhoA activity assay
RhoA activity was assessed as previously described [52]. Cells
were washed in PBS and lysed directly in 50 mM Tris pH 7.5, 1%
Triton X-100, 0.5% sodium deoxycholate, 500 mM NaCl,
10 mM MgCl2, 1 mM DTT, 0.5 mM Vanadate, 1 mM PMSF
supplemented with protease inhibitor cocktail ([Ref. P8340]
Sigma-Aldrich). Cleared lysates were precipitated with 60 mgo f
Rhotekin-RBD protein GST beads ([Ref. RT02] Cytoskeleton
Inc.) at 4uC for 1 hour. Complexes were washed in buffer
containing 50 mM Tris pH 7.5, 1% Triton X-100, 150 mM
NaCl, 10 mM MgCl2, 1 mM DTT, 1 mM PMSF supplemented
with protease inhibitor cocktail, then denatured in Laemmli
sample buffer, immunoblotted and incubated with a mouse anti-
RhoA antibody (dilution 1:300; [Ref. sc-418] Santa Cruz
Biotechnology, Inc.) followed by a HRP-conjugated sheep anti-
mouse secondary antibody (dilution 1:5,000; [Ref. NA9310] GE
Healthcare). An aliquot of the total lysate was run alongside to
quantify the total RhoA present in cell lysates in order to
determine RhoA activity as the amount of RBD-bound RhoA
relative to total RhoA; a-Tubulin expression was used to control
for equal loading.
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Cell membranes were stained in vivo by incubation with a wheat
germ agglutinin Alexa Fluor 488/350 conjugate (dilution 1:200;
[Ref. W11261, W11263] Invitrogen) diluted in HBSS (Invitrogen)
at 37uC for 10 min. Cells were then fixed in 3.65% formaldehyde,
permeabilized in 0.1% Triton X-100 for 2 min and blocked in
PBS 1% BSA at room temperature for 20 min. F-Actin was
stained by incubating cells with Phalloidin-TRITC (1 mg/mL;
[Ref. P1951] Sigma-Aldrich) at room temperature for 30 min.
DNA was stained by incubating cells with 4,6-diamidino-2-
phenylindole dihydrochloride (dilution 1:50,000; [Ref. D1306]
Invitrogen) at room temperature for 4 min. The primary
antibodies used were mouse anti-b-Tubulin (TUB 2.1) (dilution
1:200; [Ref. sc-58886]), mouse anti-b1 Integrin (102DF5) (dilution
1:200; [Ref. sc-73610]), rabbit anti-Ezrin (H-276) (dilution 1:200;
[Ref. sc-20773]), rabbit anti-PAI-1 (H-135) (dilution 1:200; [Ref.
sc-8979]), rabbit anti-uPA (H-140) (dilution 1:200; [Ref. sc-
14019]), mouse anti-uPAR (IID7) (dilution 1:200; [Ref. sc-
32765]) (all from Santa Cruz Biotechnology, Inc.), mouse anti-
ROCK1 (46) (dilution 1:200; [Ref. 611136] BD Biosciences),
rabbit anti-PDK1 (Y336) (dilution 1:200; [Ref. ab32573] Abcam)
and rabbit anti-Flotillin1 (dilution 1:200; [Ref. F1180] Sigma-
Aldrich). Cells were incubated at room temperature with the
relevant primary antibody for 2 hours and then for 1 hour with
TRITC-conjugated (dilution 1:100; [Ref. sc-3841, sc-3796] Santa
Cruz Biotechnology, Inc.) or Alexa Fluor 488-conjugated (dilution
1:100; [Ref. A11008, A11001] Invitrogen) secondary antibodies.
Slides were then mounted in Mowiol solution.
F-Actin 3D reconstruction
After incubation with Phalloidin-TRITC, the F-Actin cytoskel-
eton was observed with a 636/1.40 NA Plan Neofluar objective
lens and a laser confocal LSM 410 microscope (Zeiss). Optical
sections of cells were recorded with a z-axis of 0.2 mm and
individual frames were averaged 8 times with the line mode.
Before the 3D reconstruction, the stack of the grey level images (8
bits) was deconvoluted using the module of the Axiovision 3.0.6
software (Zeiss) which allows correcting the distortion due to the
optical system of the microscope. The fixed image data were
implemented at the appropriate scale with the Amira 2.3 software
(TGS Inc.) which uses the threshold segmentation method to
retain the details of cell cytoskeleton.
Microscopy
Phase-contrast images of fixed cells in PBS were taken using a
406/1.30 objective lens and a microscope equipped with an
AxioCam MRm vers.3 camera (Zeiss). Fluorescence images of cells
prepared as described before were taken using a 636/1.30 Plan-
Neofluar oil immersion objective lens and a Structured Illumina-
tion Microscopy (SIM) (ApoTome Axiovert 200, Zeiss), which is
an alternative method for obtaining optical sections, comparable
to confocal microscopy. Time-lapse phase-contrast recordings of
cells in medium were performed at 37uC and images were taken at
intervals of 30 s to 4 min for 5 min to 19 h with a 406/1.30
objective lens and the acquisition software AxioVision 4.0 (Zeiss).
Quantification of cell morphology
The different cell morphologies were quantified with the Cell
Counter plugin of the ImageJ software (http://rsb.info.nih.gov/ij)
using thirty to eighty phase-contrast images taken from three to
eight independent experiments (10 images/experiment). Cells
were classified in three categories: spindle-shaped, blebbing and
round cells.
Statistical analysis
Student’s unpaired t tests were performed using QuickCalcs
(GraphPad Software; www.graphpad.com/quickcalcs/index.cfm).
Signal distribution analysis
The signal distribution of a given protein along selected lines in
cells was obtained by using the Plot Profile tool of the ImageJ
software.
Colocalization analysis
The colocalization of two proteins was evaluated with the
Colocalization tool of the AxioVision software. The percentage of
colocalization of two proteins, i.e. the percentage of colocalized
pixels relative to the total number of pixels for each detected
protein, was obtained by selecting quadrants around cells and
fixing a common significant intensity threshold for the two
channels (a grey level of 100, with the background set at 25 and
the maximal signal at 1000). The mean colocalization percentage
of each stained protein and the s.e.m. were calculated by analyzing
10 cells. The colocalization images with the extracted common
pixels are shown after the merged images.
Simulation of PAI-1 deposition
We implemented two in silico models to simulate PAI-1
deposition during tumor growth. The cellular-automata model
simulates secretion, diffusion and deposition of any diffusible
protein and was implemented with the Mathematica software
(www.wolfram.com). The agent-based model considers different
processes (secretion, deposition and internalization of PAI-1,
proteolysis of the matrix and cell proliferation) and was
implemented with the NetLogo software (http://ccl.northwestern.
edu/netlogo).
Supporting Information
Figure S1 Microenvironment influence on cell morphol-
ogy. Percentage of spindle-shaped and blebbing SW620 cells
seeded in plates coated with different concentrations of PAI-1 14-
1b or collagen (from 2 to 40 mg/cm
2) at different time-points. Data
are the mean 6 s.e.m. of four independent experiments.
(TIF)
Figure S2 Cell adherence and cell growth. (A) Number of
adherent SW620 cells seeded on plates coated with PAI-1 14-1b or
collagen at different time-points (3–24 h) after seeding. Data are
the mean 6 s.e.m. of four independent experiments; *: P,0.05.
(B) Number of SW620 cells seeded on PAI-1 14-1b or collagen at
different time-points (0–72 h) after seeding. Data are the mean 6
s.e.m. of four independent experiments. F-Actin (red) and DNA
(blue) of SW620 cells seeded on PAI-1 14-1b or collagen for 19 h
were immunostained to check for DNA cleavage.
(TIF)
Figure S3 Expression of components of the Plasmino-
gen Activator system and related signaling molecules
varies according to the cell morphology and the
microenvironment. (A) PDK1 and ROCK1 expression in
blebbing SW620 cells seeded on PAI-1 14-1b or collagen at the
19 h time-point after seeding. On the right panel, quantification of
ROCK1/PDK1 colocalization relative to total ROCK1 expres-
sion in blebbing SW620 cells seeded on PAI-1 14-1b or collagen.
Data are the mean 6 s.e.m. of the results of the analysis of ten
blebbing cells for each experimental condition. Expression of (B)
uPA and uPAR, (C) PAI-1 and uPAR in blebbing SW620 cells
seeded on PAI-1 14-1b at the 19 h time-point after seeding.
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Integrin and Flotillin1 in SW620 cells seeded on PAI-1 14-1b
(30 min time-point). (F) Immunostaining of the cell membrane and
uPA in SW620 cells seeded on PAI-1 14-1b (30 min time-point).
Bar, 5 mm.
(TIF)
Figure S4 Role of the Plasminogen Activator system in
cell migration. The Plasminogen Activator system is primarily
associated with the proteolytic type of cell migration where active
uPA catalyzes the cleavage of Plasminogen into Plasmin which in
turn facilitates the release of several proteolytic enzymes and the
degradation of the extracellular matrix [A] [53,54]. The principal
uPA inhibitor, PAI-1, inhibits the proteolytic activity of uPA [B]
[55]. When PAI-1 is bound to Vitronectin (VN), a major matrix
component, and uPA to its surface receptor uPAR, the [uPA:PAI-
1] complex forms a molecular link between cell and matrix that
can allow the transmission of an intracellular mechanical signal
[C] [32] and results in the internalization of the whole complex by
the a2-Macroglobulin Receptor/Low-density Lipoprotein Recep-
tor (a2-MR/LRP) [D] [35,56]. Then the [uPA:PAI-1] complex is
degraded by lysosomes [E] [55,57] and uPAR and LRP are
recycled [F] [35]. uPAR also promotes cell adhesion through its
interaction with VN in the extracellular matrix and can transmit
an intracellular biochemical signal via Integrins [G] [27].
However, active PAI-1, independently of its role as a protease
inhibitor, inhibits uPAR adhesion by blocking uPAR binding to
VN [H] [16,18]. Active PAI-1 also inhibits Integrin- and VN-
mediated cell migration by blocking binding of avb3 Integrin to
VN [I] [19,54].
(TIF)
Figure S5 Agent-based simulation of matrix-bound PAI-
1 accumulation at the tumor periphery. In this simulation
several physiological processes, such as PAI-1 secretion, deposition
and internalization, proteolysis of the matrix and cell proliferation
are taken into account (see also Video S5).
(TIF)
Video S1 Motility of blebbing SW620 cells seeded on
immobilized, active PAI-1. Time-lapse recording of blebbing
SW620 cells 3 h after seeding on PAI-1 14-1b. Images were
captured every 2 min. Bar, 10 mm.
(MOV)
Video S2 PAI-1 expression in SW620 cells seeded on
non-coated plates. The z-stack video shows details of the
immunostaining of the cell membrane (red) and of PAI-1
expression (green) from the slide to the upper part of a SW620
cell seeded on non-coated plate for 30 min. Bar, 5 mm.
(MOV)
Video S3 Flotillin1 and PAI-1 expression in SW620 cells
seeded on non-coated plates. The z-stack video shows details
of Flotillin1 (red) and PAI-1 (green) from the slide to the upper part
of a SW620 cell seeded on non-coated plate for 30 min. Bar,
5 mm.
(MOV)
Video S4 PDK1 and ROCK1 expression in SW620 cells
seeded on immobilized, active PAI-1. The z-stack video
shows details of PDK1 (red) and ROCK1 (green) from the slide to
the upper part of a SW620 cell seeded on PAI-1 14-1b for 30 min.
Bar, 5 mm.
(MOV)
Video S5 Agent-based simulation of matrix-bound PAI-
1 accumulation at the tumor periphery. Several physiolog-
ical processes are considered such as secretion, deposition and
internalization of PAI-1, proteolysis of the matrix and cell
proliferation. See color legend in Figure S5.
(MOV)
Video S6 Migration of a blebbing SW620 cell on
immobilized, active PAI-1. Time-lapse recording of SW620
cells 17 h after seeding on PAI-1 14-1b. The migration speed was
evaluated at 0.4 mm/min. Images were captured every 2 min. Bar,
10 mm.
(MOV)
Video S7 Reversibility of the blebbing and spindle-
shaped morphologies in SW620 cells seeded on immo-
bilized, active PAI-1. Time-lapse recording of SW620 cells 7 h
after seeding on PAI-1 14-1b. Images were captured every 2 min.
Bar, 10 mm.
(MOV)
Video S8 Reversibility of the blebbing morphology in
SW620 cells seeded on immobilized, active PAI-1. Time-
lapse recording of SW620 cells 16 h after seeding on PAI-1 14-1b.
Images were captured every 2 min. Bar, 10 mm.
(MOV)
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